News Releases

Date	Title and Summary	View
May 24, 2021	Janssen’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
May 23, 2021	Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn’s Disease
May 21, 2021	RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021	Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
May 19, 2021	Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021	IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, FirstLine Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 16, 2021	Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
May 13, 2021	Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa Up to 200,000 Johnson & Johnson Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone Company's Ebola vaccine regimen also receives Prequalification from the WHO The Johnson & Johnson vaccine regimen is designed to be used
May 12, 2021	Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management
May 07, 2021	Johnson & Johnson to Participate in Goldman Sachs 42nd Annual Global Healthcare Virtual Conference